Back to Search Start Over

Cost‒utility analysis of breast reduction surgery for women with symptomatic breast hypertrophy

Authors :
Christine Mpundu-Kaambwa
Julie Ratcliffe
Nicola R. Dean
Tamara Crittenden
David I. Watson
Source :
Medical Journal of Australia. 216:147-152
Publication Year :
2021
Publisher :
Wiley, 2021.

Abstract

Objective To assess the cost-effectiveness of breast reduction surgery for women with symptomatic breast hypertrophy in Australia. Design Cost-utility analysis of data from a prospective cohort study. Setting, participants Adult women with symptomatic breast hypertrophy assessed for bilateral breast reduction at the Flinders Medical Centre, a public tertiary hospital in Adelaide, April 2007 - February 2018. The control group included women with breast hypertrophy who had not undergone surgery. Main outcome measures Health care costs (for the surgical admission and other related hospital costs within 12 months of surgery) and SF-6D utility scores (measure of health-related quality of life) were used to calculate incremental costs per quality-adjusted life-year (QALY) gained over 12 months, extrapolated to a 10-year time horizon. Results Of 251 women who underwent breast reduction, 209 completed the baseline and at least one post-operation assessment (83%; intervention group); 124 of 350 invited women waiting for breast reduction surgery completed the baseline and 12-month assessments (35%; control group). In the intervention group, the mean SF-6D utility score increased from 0.313 (SD, 0.263) at baseline to 0.626 (SD, 0.277) at 12 months; in the control group, it declined from 0.296 (SD, 0.267) to 0.270 (SD, 0.257). The mean QALY gain was consequently greater for the intervention group (adjusted difference, 1.519; 95% CI, 1.362-1.675). The mean hospital cost per patient was $11 857 (SD, $4322), and the incremental cost-effectiveness ratio (ICER) for the intervention was $7808 per QALY gained. The probability of breast reduction surgery being cost-effective was 100% at a willingness-to-pay threshold of $50 000 per QALY and 88% at $28 033 per QALY. Conclusions Breast reduction surgery for women with symptomatic breast hypertrophy is cost-effective and should be available to women through the Australian public healthcare system.

Details

ISSN :
13265377 and 0025729X
Volume :
216
Database :
OpenAIRE
Journal :
Medical Journal of Australia
Accession number :
edsair.doi.dedup.....2a9a006768ac2f1ba2ebb33109b6f6f3
Full Text :
https://doi.org/10.5694/mja2.51343